H6PD expression was significantly positively correlated with CD274, CTLA4, LAG3, PDCD1LG2, TIGHT, and SIGLEX15, indicating that targeting H6PD might increase the efficacy of immunotherapy in GBM. The gene discussed is CTLA4; the disease is glioblastoma.